• Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., said the Sarah Cannon Research Institute in Nashville opened enrollment in a Phase I study testing MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small-cell lung cancers.